HC Wainwright Issues Pessimistic Outlook for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at HC Wainwright dropped their FY2025 EPS estimates for shares of Zevra Therapeutics in a research note issued on Thursday, March 13th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings per share of ($0.32) for the year, down from their prior estimate of ($0.23). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ FY2026 earnings at $0.58 EPS, FY2027 earnings at $1.48 EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $2.51 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The company had revenue of $12.00 million during the quarter, compared to analysts’ expectations of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%.

A number of other research firms have also weighed in on ZVRA. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Guggenheim raised their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, March 13th. Cantor Fitzgerald reissued an “overweight” rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Finally, Canaccord Genuity Group raised their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, March 13th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $22.14.

Zevra Therapeutics Trading Up 0.5 %

ZVRA opened at $8.35 on Monday. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company’s 50 day simple moving average is $7.92 and its two-hundred day simple moving average is $8.17. Zevra Therapeutics has a 1-year low of $4.20 and a 1-year high of $9.76. The firm has a market capitalization of $451.87 million, a price-to-earnings ratio of -4.24 and a beta of 1.98.

Insider Activity at Zevra Therapeutics

In related news, CFO R. Laduane Clifton sold 11,000 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $86,460.00. Following the completion of the sale, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. This trade represents a 17.64 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 85,773 shares of company stock worth $674,176. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Zevra Therapeutics

Several institutional investors have recently modified their holdings of the business. MetLife Investment Management LLC grew its stake in shares of Zevra Therapeutics by 8.1% in the third quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock worth $159,000 after acquiring an additional 1,717 shares in the last quarter. IFG Advisors LLC grew its stake in shares of Zevra Therapeutics by 10.0% in the fourth quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock worth $242,000 after acquiring an additional 2,650 shares in the last quarter. Invesco Ltd. lifted its position in shares of Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock worth $153,000 after purchasing an additional 3,007 shares during the last quarter. Corebridge Financial Inc. lifted its position in shares of Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock worth $219,000 after purchasing an additional 3,801 shares during the last quarter. Finally, Squarepoint Ops LLC lifted its position in shares of Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock worth $138,000 after purchasing an additional 4,384 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.